Singapore: China Biologic Products has acquired an additional 19.84 percent equity interest in Guizhou Taibang Biological Products, raising shares from 56.39 percent to 76.23 percent.

China Biologic is a plasma-based biopharmaceutical company in China. The company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases.